Primary and secondary metastatic dissemination: multiple routes to cancer-related death

D Sparrer1,2, R Blazquez3, F Keil4

  • 1Center for Translational Oncology, University Hospital Regensburg, Regensburg, 93053, Germany.

Molecular Cancer
|July 22, 2025
PubMed

Insights

Metastatic cancer causes most cancer deaths, often leading to organ failure. Understanding organ-specific spread and destruction is key to developing new therapies that preserve organ function.

Area of Science:

  • Oncology
  • Pathophysiology
  • Cancer Metastasis

Background:

  • Metastatic disease is responsible for approximately 80% of cancer-related deaths.
  • Organ failure, often due to abdominal, cardiovascular, neurological, or respiratory complications, is the primary cause of mortality.
  • Current understanding of organ-specific metastatic routes and tissue destruction mechanisms remains limited.

Purpose of the Study:

  • To enhance understanding of organ-specific metastatic dissemination and destruction.
  • To elucidate the pathophysiology of secondary and subsequent metastatic waves.
  • To highlight the emerging therapeutic goal of maintaining organ function in cancer care.

Main Methods:

  • Literature review and synthesis of current research on metastatic biology.
  • Analysis of clinical data related to metastatic disease progression and organ failure.
  • Development of a conceptual model aligning metastatic biology with clinical goals of care.

Main Results:

  • Distinguishing primary metastatic spread from secondary intra-organ dissemination is critical.
  • Understanding organ-specific destruction processes is fundamental for advancing patient care.
  • The Bio Therapeutic Goals of Cancer Care Model integrates metastatic biology, clinical stages, and therapeutic indications.

Conclusions:

  • Maintaining organ function is an emerging critical therapeutic goal in cancer care.
  • Elucidating the pathophysiology of metastatic waves is essential for developing effective treatments.
  • The Bio Therapeutic Goals of Cancer Care Model provides a framework for aligning research and clinical practice.

Related Concept Videos

Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.7K
Cancer Cell Migration through Invadopodia01:35

Cancer Cell Migration through Invadopodia

Invadosome is a broad category of cell surface structures with proteolytic activity that  degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
2.4K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K